ClinicalTrials.gg
Not yet recruitingNCT07849634Updated Nov 20, 2026

Pain, Central Sensitization, and Misophonia in Lipedema

An observational study in Lipedema, sponsored by Gaziantep City Hospital. Not yet recruiting. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Gaziantep City Hospital · Observational

How we know

Updated Nov 20, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
70
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

Lipedema is a chronic condition that predominantly affects women and is characterized by disproportionate, usually symmetrical accumulation of subcutaneous fat, particularly in the hips and legs. Pain, tenderness, easy bruising, fatigue, and psychological symptoms may substantially affect daily functioning and quality of life. Misophonia involves intense negative reactions to specific sounds, but its relationship with lipedema remains unclear.

This observational case-control study aims to investigate misophonia symptoms in women with lipedema compared with women without lipedema and to explore their associations with pain and psychosocial factors. The prespecified primary outcome measure is central sensitization severity, assessed using the Central Sensitization Inventory. Secondary outcome measures include misophonia symptom severity, pain intensity, pressure pain thresholds, pain catastrophizing, sleep quality, depressive and anxiety symptoms, and body image. The study will compare these outcomes between groups and examine their associations with misophonia symptoms.

Read the detailed description

Lipedema is a chronic condition characterized by a disproportionate, usually symmetrical accumulation of subcutaneous adipose tissue, predominantly in the hips, thighs, and legs. The arms may also be affected. It occurs almost exclusively in women and can substantially affect daily functioning, quality of life, and psychosocial well-being. Commonly reported symptoms include pain, tenderness, easy bruising, and a sensation of swelling. Fatigue, walking difficulties, sleep problems, and symptoms of depression or anxiety may also occur. Misophonia involves intense negative reactions to specific sounds, such as chewing, breathing, or pen clicking. Given the symptom burden associated with lipedema, investigating misophonia symptoms in this population may provide insight into their relationship with pain, central sensitization, and psychological well-being.

This observational case-control study will investigate central sensitization and its relationship with misophonia and other clinical symptoms in women with lipedema. Women aged 18-65 years who provide written informed consent will be eligible for assessment. Participants with a Lipedema Screening Questionnaire score of ≥9 and a clinical diagnosis of lipedema will be included in the case group. Women with a score of \<9 will be included in the control group. The screening questionnaire will support group allocation but will not serve as the sole basis for a clinical diagnosis.

Demographic and clinical data will include age, marital status, education, occupation, menopausal status, parity, smoking and alcohol use, body mass index, systemic diseases, medications, family history, and exercise habits. For participants with lipedema, the duration of diagnosis, disease stage and type, affected body regions, age at pain onset, and clinical features-including pain, tenderness, easy bruising, perceived swelling, and symmetric or asymmetric involvement-will be recorded. Previous treatments, including dietary interventions, compression garments, liposuction, complex decongestive therapy, and other reported interventions, will also be documented.

The primary outcome will be central sensitization severity, assessed using the Central Sensitization Inventory. Secondary outcomes will include pain intensity measured with a visual analog scale; pressure pain thresholds measured by algometry at the bilateral deltoid regions, lateral thighs, and medial aspects of the knees; pain catastrophizing assessed with the Pain Catastrophizing Scale; sleep quality assessed with the Pittsburgh Sleep Quality Index; depressive symptoms assessed with the Beck Depression Inventory; anxiety symptoms assessed with the Beck Anxiety Inventory; and body image assessed with the Body Image Scale. Misophonia symptoms will be assessed using a Misophonia Scale.

The study will compare these measures between the lipedema and control groups and examine associations between misophonia symptoms, central sensitization, pain, and psychological measures.

02

Conditions studied

  • Lipedema

Browse trials for

Keywords

  • Lipedema
  • Central Sensitization
  • Misophonia
  • Pain
  • Psychological Factors
  • Pressure Pain Threshold
03

In context

Lipedema

85 studies on the registry are indexed under Lipedema; 31 are open to participants now.

This study's planned enrollment of 70 is below the median of 90 across 42 observational studies indexed under Lipedema.

Browse Lipedema studies →

Lead sponsor

Gaziantep City Hospital is the lead sponsor of 21 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of women aged 18-65 years recruited for an observational case-control study. The case group will comprise women with a clinical diagnosis of lipedema based on medical history and physical examination and a Lipedema Screening Questionnaire score of ≥9. The control group will comprise women without clinical evidence of lipedema and with a questionnaire score of \<9. Eligible participants will provide written informed consent and complete assessments of misophonia, central sensitization, pain, sleep, psychological symptoms, and body image, as well as pressure pain threshold measurements.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female sex.
  • Age 18-65 years.
  • Case group: Clinical diagnosis of lipedema based on medical history and physical examination, and a Lipedema Screening Questionnaire score of ≥9.
  • Control group: No clinical diagnosis of lipedema based on medical history and physical examination, and a Lipedema Screening Questionnaire score of \<9.
  • Willingness to participate and provision of written .

Exclusion criteria

Exclusion Criteria:

  • Primary or secondary lymphedema.
  • Active or infection.
  • Severe immobility or advanced venous insufficiency.
  • A history of major surgery, trauma, or serious systemic illness within the past six months.
  • Pregnancy or breastfeeding.
  • A diagnosed neuropsychiatric disorder, such as schizophrenia, schizoaffective disorder, or bipolar disorder.
  • A history of ear or hearing disorders.
  • A diagnosed neurological disorder, such as epilepsy, multiple sclerosis, stroke, or dementia.
  • Current substance use disorder or use of psychotropic medication within the past 30 days.
  • Inability to understand or complete the study procedures because of language, cognitive, or sensory limitations.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Women With Lipedema

    Women aged 18-65 years with a clinical diagnosis of lipedema and a Lipedema Screening Questionnaire score of ≥9. Participants will complete questionnaires and undergo pressure pain threshold measurements. No intervention will be administered.

  • Women Without Lipedema

    Women aged 18-65 years without a clinical diagnosis of lipedema and with a Lipedema Screening Questionnaire score of \<9. Participants will complete the same questionnaires and undergo the same pressure pain threshold measurements. No intervention will be administered.

06

What researchers measure

Primary outcomes

  1. Central Sensitization Inventory (CSI)

    The CSI consists of 25 items. Each item is scored on a five-point scale: never (0), rarely (1), sometimes (2), often (3), and always (4). Total scores range from 0 to 100, with higher scores indicating greater symptom severity. A score of 40 is used as the cutoff.

    Time frame: Baseline, at the time of clinical assessment

Secondary outcomes

  1. Visual Analog Scale (VAS)

    Pain intensity will be assessed using a 10-cm horizontal line anchored by "no pain" at one end and "worst imaginable pain" at the other. Participants will mark the point that best represents their pain intensity. The distance from the left end of the line to the mark will be recorded in centimeters; higher values indicate greater pain intensity.

    Time frame: Baseline, at the time of clinical assessment

  2. Pain Catastrophizing Scale (PCS)

    The PCS is a 13-item self-report questionnaire used to assess catastrophic thoughts and feelings related to pain in clinical and nonclinical populations. Its items cover three dimensions: rumination, magnification, and helplessness. Each item is scored from 0 to 4 on a five-point scale, yielding a total score of 0-52. Higher scores indicate greater pain catastrophizing.

    Time frame: Baseline, at the time of clinical assessment

  3. Pressure Pain Threshold Measurement by Algometry

    Pressure pain threshold (PPT) is the minimum applied pressure at which a participant first perceives pain. A pressure algometer with a 1 cm² probe tip will be applied perpendicular to the skin, and pressure will be increased at a rate of approximately 1 kg/cm² per second. Participants will be instructed to indicate when the pressure first becomes painful. PPT will be measured bilaterally at the deltoid regions, lateral thighs, and medial aspects of the knees. Higher PPT values indicate lower sensitivity to pressure-induced pain.

    Time frame: Baseline, at the time of clinical assessment

  4. Beck Depression Inventory (BDI)

    The BDI is a standardized self-report instrument developed by Aaron T. Beck to assess the severity of depressive symptoms. The validity and reliability of its Turkish version were established by Nihal Hisli. Higher scores indicate more severe depressive symptoms.

    Time frame: Baseline, at the time of clinical assessment

  5. Beck Anxiety Inventory (BAI)

    The BAI is a 21-item self-report questionnaire used to assess the severity of anxiety symptoms experienced during the past week. It places particular emphasis on somatic symptoms of anxiety. Each item is scored from 0 to 3, yielding a total score of 0-63; higher scores indicate more severe anxiety symptoms.

    Time frame: Baseline, at the time of clinical assessment

  6. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-report questionnaire developed by Buysse and colleagues in 1989 to assess sleep quality and sleep disturbances over the past month. The validity and reliability of its Turkish version were evaluated by Ağargün and colleagues in 1996. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Baseline, at the time of clinical assessment

  7. Misophonia Scale

    The scale assesses sensitivity to specific sounds, such as eating sounds, repetitive tapping, rustling, and breathing sounds. Participants first rate their sensitivity to these sounds from 0 ("not at all true") to 4 ("always true"). Those reporting any sound sensitivity then rate how often the sounds lead to avoidance, emotional distress, anger, or aggressive responses, using a scale from 0 ("never") to 4 ("always"). Finally, participants rate the overall severity of their sound sensitivity on a separate 1-15 scale, taking into account its intensity and impact on daily life.

    Time frame: Baseline, at the time of clinical assessment

  8. Body Image Scale (BIS)

    The BIS, developed by Saylan and Soyyiğit, is a 21-item instrument used to assess body image. It comprises four subscales: Sensitivity to Evaluation, Negative Body Perception, Positive Body Perception, and Body Modification. Item scores are summed to obtain a total score ranging from 21 to 105. Higher total scores indicate a more negative body image.

    Time frame: Baseline, at the time of clinical assessment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data will be available from the corresponding author upon reasonable request. These data may include age, body mass index, study group, questionnaire scores, pressure pain threshold measurements, and relevant lipedema-related clinical characteristics. Direct personal identifiers will be removed before any data are shared to protect participant confidentiality.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will be available after publication of the study results.

Access criteria: De-identified individual participant data and supporting documents will be available to qualified researchers upon reasonable request to the principal investigator. Access will be granted for scientific research purposes after approval of the research proposal. Data will be shared through secure electronic transfer.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Sep 2026 → Nov 2026, primary completion Nov 2026 → Jan 2027 and completion Dec 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Nov 19, 2026was Sep 2026
Primary completionEst.
Jan 29, 2027was Nov 2026
CompletionEst.
Feb 7, 2027was Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 28, 2026→Nov 19, 2026
Nov 20, 2026
Primary completion
Nov 23, 2026→Jan 29, 2027
Nov 20, 2026
Study completion
Dec 7, 2026→Feb 7, 2027
Nov 20, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Nov 20, 2026
    Start date Sep 28, 2026→Nov 19, 2026
    Primary completion Nov 23, 2026→Jan 29, 2027
    Study completion Dec 7, 2026→Feb 7, 2027
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849634
Lead sponsor
Gaziantep City Hospital
Responsible party
Merve Önoğul Özmen (Consultant, Gaziantep City Hospital) — Principal investigator
First posted
Sep 30, 2026
Start date
Nov 19, 2026 (estimated)
Primary completion
Jan 29, 2027 (estimated)
Completion
Feb 7, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Merve ÖNOĞUL ÖZMEN, Medıcal Doctor
Contact
drmerveonogul@gmail.com
05398981401 ext. +(0312)7970000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion